News

Bio-IT World || Lessons From the Recent HCA 2022 General Meeting: Applying Single-Cell Data to Clinical Decision Making

The recent Human Cell Atlas (HCA) 2022 General Meeting, hosted in Vienna, Austria, provided a great opportunity for me to catch up on progress towards the HCA’s goal of mapping every cell type in the human body. I also got the chance to hear presentations that either highlighted new insights gleaned from HCA data or described the outcomes from ongoing collaborations between research groups.

whitepages icon x

International Pharmaceutical Technology | 1 Trillion Cells, 50 Million Individuals

Calculating the true value of scientific data storage platforms is the goal of every developer. With millions of cells to analyze, digital solutions are the key

whitepages icon x

datanami | Key Questions to Ask of Your Scientific Data Platform for Single Cell Analysis

The idea of precision medicine – delivering the right drug treatment to the right patient at the right time and at the right dose – underpins current thinking in pharma R&D. by Zach Pitluk

whitepages icon x

Foundational partnership with Paradigm4 enables Alnylam Pharmaceuticals to rapidly accelerate RNAi- based drug target discovery

25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified